Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytochalasin B
- Development stage
- Unknown
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intracoronary (experimental/local Delivery At Angioplasty Site)[3], Intraperitoneal (animal Studies)[8], Note That Other Routes Such As Oral, Dermal, Inhalation Are Possible Only Through Accidental Or Experimental Exposure[9].
01
Overview
Cytochalasin B is a cell-permeable mycotoxin and alkaloid isolated from fungi such as Helminthosporium dematioideum and species of the Phoma genus. It is widely used in research for its ability to inhibit actin polymerization by binding to the fast-growing (barbed) end of F-actin filaments, thereby blocking cytoplasmic division, inhibiting cell movement, and inducing nuclear extrusion. Cytochalasin B also inhibits glucose transporters (GLUT1, GLUT3, GLUT4), platelet aggregation, and can induce apoptosis in certain cancer cell lines. It has been investigated experimentally for potential use in preventing restenosis after angioplasty due to its effects on vascular remodeling but is not approved for clinical use. Its primary applications remain experimental and research-focused[2][3][5][6][8].
- Other names
- Phomin
02
Targets
SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)GLUT1 (Glucose transporter 1)F-actin (Filamentous actin)SLC2A3 (Glucose transporter type 3)
Beyond the preview
Go deeper on cytochalasin B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytochalasin B.